Affiliation:
1. Obstetrics and Gynecology, Umraniye Training and Research Hospital,
Istanbul, Turkey
Abstract
Abstract
Objective We aimed to investigate the relationship between gestational
diabetes mellitus (GDM) and maternal serum hepassocin concentrations.
Materials and methods This cross-sectional study was conducted with 88
pregnant women who applied to the Ümraniye Training and Research
Hospital Gynecology and Obstetrics Clinic between April 2022 and November 2022.
The GDM group consisted of 44 pregnant women who had a 75-g OGTT between the
24th and 28th week of pregnancy and were diagnosed with GDM. The control group
consisted of 44 healthy pregnant women who were matched with the GDM group in
terms of age and body mass index (BMI) and had a normal 75-g OGTT result.
Demographic characteristics, laboratory findings, and perinatal outcomes were
noted. Two groups were compared in terms of maternal serum hepassocin
concentrations.
Results Both groups were similar in terms of age, BMI, weight gain,
gravida, parity, polycystic ovary syndrome history, history of diabetes mellitus
in the family, and the gestational week at blood sampling for hepassocin
(p>0.05 for each). The median maternal serum hepassocin concentration
was found to be 18.21 ng/ml in the GDM group, while it was
determined as 13.05 ng/ml in the non-GDM group
(p=0.012). The GDM group was divided into two groups: the group that
only dieted until birth and the group that used insulin until birth for blood
glucose regulation. The median hepassocin concentration was found to be
17.99 ng/ml in the diet-only GDM group and
32.15 ng/ml in the insulin-using GDM group. ROC analysis was
performed to determine the value of maternal serum hepassocin concentration in
predicting GDM. AUC analysis of maternal serum hepassocin for estimation of GDM
was 0.656 (p=0.012, 95% CI=0.53–0.77). The
optimal threshold value for maternal serum hepassocin concentration was
determined as 14.13 ng/ml with 61.4% sensitivity and
61.4% specificity.
Conclusion Serum hepassocin concentration evaluated between 24 and 28
weeks of gestation was found to be higher in pregnant women with GDM than in the
non-GDM group. The highest serum hepassocin concentration was found in the GDM
group using insulin for blood glucose regulation. Hepassocin seems to be a
promising molecule that can be used in GDM screening in pregnant women who do
not want to have an OGTT in the future.
Subject
Maternity and Midwifery,Obstetrics and Gynecology,Pediatrics, Perinatology and Child Health
Reference23 articles.
1. No. 190: Gestational Diabetes Mellitus;ACOG Practice Bulletin;Obstet Gynecol,2018
2. Crıterıa for the oral glucose tolerance test ın
pregnancy;J B O’sullivan;Diabetes,1964
3. Gestational diabetes: Overview with emphasis on medical management;M Lende;Int J Environ Res Public Health,2020
4. A clinical update on gestational diabetes mellitus;A Sweeting;Endocr Rev,2022